Ther Adv Endocrinol Metab. 2012 Feb;3(1):27-47. doi: 10.1177/2042018812437355.
Polycystic ovary syndrome (PCOS) is a common endocrine disorder in women of reproductive age that is associated with significant adverse short- and long-term health consequences. Multiple metabolic aberrations, such as insulin resistance (IR) and hyperinsulinaemia, high incidence of impaired glucose tolerance, visceral obesity, inflammation and endothelial dysfunction, hypertension and dyslipidemia are associated with the syndrome. Assessing the metabolic aberrations and their long term health impact in women with PCOS is challenging and becomes more important as therapeutic interventions currently available for the management of PCOS are not fully able to deal with all these consequences. Current therapeutic management of PCOS has incorporated new treatments resulting from the better understanding of the pathophysiology of the syndrome. The aim of this review is to summarize the effect of old, new and emerging therapies used in the management of PCOS, on the metabolic aberrations of PCOS.
多囊卵巢综合征（PCOS）是一种常见的育龄期女性内分泌疾病，与多种短期和长期不良健康后果密切相关。多种代谢异常，如胰岛素抵抗（IR）和高胰岛素血症、葡萄糖耐量受损发生率高、内脏肥胖、炎症和内皮功能障碍、高血压和血脂异常，与该综合征有关。评估 PCOS 患者的代谢异常及其长期健康影响具有挑战性，而且随着目前用于 PCOS 管理的治疗干预措施不能完全应对所有这些后果，这种评估变得更加重要。目前 PCOS 的治疗管理已经纳入了由于对该综合征病理生理学的更好理解而产生的新治疗方法。本综述的目的是总结用于 PCOS 管理的旧、新和新兴疗法对 PCOS 代谢异常的影响。
